MTEM is a clinical stage Biotechnology company focused on the discovery, development and commercialization of next generation immunotoxins called engineered toxin bodies (ETBs for the treatment of cancer. Backed by a very strong syndicate of investors, MTEM went public via Reverse Merger in August 2017. In June of 2018 we were introduced to MTEM by a board member of the company. This same board member appreciated the work we had done for a couple other companies where he is also a board member and thought we could be a value-add partner. At the time that we met in mid-2018, in our opinion, they were under followed and undervalued. We then consummated a robust 2-3-month Non-Deal roadshow and in September of 2018, MTEM raised ~$45,000,000 to strengthen what was already a strong balance sheet. This follow-on offering was led by Cowen and Company, Evercore and UBS and Laidlaw acted as Lead Manager. Many of the healthcare centric institutions that we introduced MTEM to participated in the financing in a meaningful way. The company continued to work with their financial sponsors, and also add of a couple strategic partnerships to their story throughout 2019 and In November of 2019, MTEM successfully Raised $50,000,000 lead by Cowen, Barclays and Stifel. Laidlaw acted as a Financial Advisor on the transaction. We continue to pound the table on the name and be a supportive partner to the company.